药明康德(02359) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 reached approximately RMB 10.64 billion, representing a year-on-year increase of 77.76%[6] - Net profit attributable to shareholders for the same period was approximately RMB 2.74 billion, reflecting a significant increase of 209.11% year-on-year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately RMB 2.38 billion, up 143.31% compared to the previous year[6] - The basic earnings per share for Q3 2022 was RMB 0.93, an increase of 210.00% year-on-year[6] - The diluted earnings per share was RMB 0.81, showing a year-on-year increase of 170.00%[6] - The company's operating revenue for the first three quarters of 2022 reached RMB 28,394.56 million, representing a year-on-year increase of 71.9%[13] - The net profit attributable to shareholders of the listed company for the current reporting period was RMB 2,091.10 million, with a year-to-date figure of RMB 1,071.20 million[8] - The company achieved a basic earnings per share of RMB 2.10 for the current reporting period, compared to RMB 1.07 for the year-to-date[9] - Total revenue for the first three quarters of 2022 reached ¥28,394,561,790.41, a significant increase of 72% compared to ¥16,521,369,391.37 in the same period of 2021[30] - Operating profit for the first three quarters of 2022 was ¥8,842,196,326.34, up from ¥4,302,311,952.74 in 2021, reflecting a growth of approximately 105.5%[30] - Net profit attributable to shareholders for the first three quarters of 2022 was ¥7,377,913,928.98, compared to ¥3,562,226,936.53 in 2021, indicating an increase of about 106%[31] Assets and Liabilities - The total assets attributable to shareholders reached approximately RMB 65.75 billion, a year-on-year increase of 19.27%[6] - The equity attributable to shareholders was approximately RMB 44.81 billion, reflecting a year-on-year increase of 16.42%[6] - Total liabilities as of September 30, 2022, amounted to ¥20,612,129,366.80, up from ¥16,369,925,768.22 at the end of 2021, representing a growth of approximately 26.5%[29] - The company's total equity reached ¥45,137,087,394.70 as of September 30, 2022, compared to ¥38,757,462,615.81 at the end of 2021, marking an increase of about 16.3%[29] - The company's total assets reached RMB 65,749,216,761.50 as of September 30, 2022, compared to RMB 55,127,388,384.03 at the end of 2021[27] - The company's total current liabilities increased to ¥17,473,856,415.48 as of September 30, 2022, from ¥12,984,593,869.40 in 2021, representing a growth of about 34.3%[28] Revenue Sources - Revenue from the chemical business (WuXi Chemistry) was RMB 20,816.66 million, up 106.6% from RMB 10,077.19 million in the same period last year[13] - Revenue from U.S. customers was RMB 18,991 million, a year-on-year increase of 110%[12] - Revenue from existing customers was RMB 27,546 million, reflecting an 80% year-on-year growth[12] - The company’s revenue from the top 20 global pharmaceutical companies was RMB 12,918 million, marking a 21% year-on-year increase[12] Customer and Workforce - The company served over 5,900 active clients from more than 30 countries as of the end of the reporting period[5] - The workforce comprised 45,646 employees, with 13,488 holding master's degrees or higher, and 1,379 holding doctoral degrees[5] - The company added over 1,000 new customers in the first three quarters of 2022, with active customer numbers exceeding 5,900[12] Research and Development - Research and development expenses for the first three quarters of 2022 were ¥1,089,268,152.01, compared to ¥644,205,887.55 in 2021, reflecting a rise of approximately 69.2%[30] - The company’s CRDMO service revenue continues to grow rapidly, with a total of 2,123 new drug molecules involved in chemical business services as of Q3 2022, including 53 in Phase III, 288 in Phase II, and 1,738 in preclinical stages[14] - The number of customers for D&M services in the oligonucleotide and peptide drug sector reached 97, a year-on-year increase of 98%, with service revenue reaching RMB 1.1 billion, a year-on-year growth of 406%[14] Cash Flow and Investments - The company reported a net cash flow from operating activities of RMB 14,238 million for the year-to-date[9] - The net cash flow from operating activities for the first three quarters of 2022 was RMB 770,965.05 million, representing a year-on-year increase of 142%[20] - The company reported a net cash outflow from investing activities of RMB 5,846,717 thousand in the first three quarters of 2022, compared to RMB 4,161,234 thousand in the same period of 2021[41] - The company paid dividends totaling RMB 1,529,442 thousand in the first three quarters of 2022, an increase from RMB 892,980 thousand in the same period of 2021[42] Future Outlook and Plans - The company announced plans for a new base in Singapore and commenced construction of a new production base in Middletown, Delaware, to better meet global partner needs[14] - The company adjusted its full-year revenue growth target for 2022 from 68-72% to 70-72%, reflecting confidence in its CRDMO and CTDMO business models[20] - The company emphasizes that its 2022 performance outlook is based on current order status and various external factors, indicating significant uncertainty[20]